Pathogenesis of ascites in cirrhosis

Seminars in Liver Disease

Volumn 17, Issue 3, 1997, Pages 175-189

  Ginès, Pere ^a   Fernández Esparrach, Glòria ^a   Arroyo, Vicente ^a   Rodés, Joan ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Edema; Renal dysfunction; Vasoactive systems

Indexed keywords

ARTERY BLOOD FLOW; ASCITES; DISEASE SEVERITY; EFFECTOR CELL; EXTRACELLULAR FLUID; HEART OUTPUT; HEPATORENAL SYNDROME; HUMAN; KIDNEY DISEASE; LIVER CIRRHOSIS; PATHOGENESIS; PERITONEAL CAVITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; SODIUM RETENTION; URINARY EXCRETION; VASOCONSTRICTION; WATER RETENTION;

EID: 0030930855     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007196     Document Type: Review

References (183)

1. González-Campoy JM, Knox FG: Integrated responses of the kidney to alterations in extracellular fluid volume. In: Seldin DW, Giebisch G (eds): The kidney: Physiology and pathophysiology (ed 2). New York, Raven Press, 1992.
2. Robertson GL, Berl T: Pathophysiology of water metabolism. In: Brenner BM, Rector FC (eds): The Kidney (ed 4). Philadelphia, W. B. Saunders, 1991.
3. Ginès P, Arroyo V, Rodés J: Disorders of renal function in cirrhosis: pathophysiology and clinical aspects. In: Zakim D, Boyer TD (eds): Hepatology: a textbook of liver disease (ed 3). Philadelphia, W. B. Saunders, 1996.
4. Farnsworth EB, Krakusin JS: Electrolyte partition in patients with edema of various origins. J Lab Clin Med 33:1545-54, 1948.
5. Falloon WW, Eckhardt RD, Cooper AM, Davidson CS: The effect of human serum albumin, mercurial diuretics, and a low sodium diet on sodium excretion in patients with cirrhosis of the liver. J Clin Invest 28:595-602, 1949.
6. Eisenmenger WJ, Blondheim SH, Bongiovanni AM, Kunkel HG: Electrolyte studies on patients with cirrhosis of the liver. J Clin Invest 29:1491-9, 1950.
7. Arroyo V, Rodés J: A rational approach to the treatment of ascites. Postgrad Med J 51:558-62, 1975.
8. Levy M: Sodium retention and ascites formation in dogs with experimental portal cirrhosis. Am J Physiol 233:F572-85, 1977.
9. Levy M, Allotey JB: Temporal relationships between urinary salt retention and altered systemic hemodynamics in dogs with experimental cirrhosis. J Lab Clin Med 92:560-9, 1978.
10. López-Novoa JM, Rengel MA, Hernando L. Dynamics of ascites formation in rats with experimental cirrhosis. Am J Physiol 238:F353-7, 1980.
11. Jiménez W, Martínez-Pardo A, Arroyo V, et al: Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology 5:245-50, 1985.
12. Gliedman ML, Carrol HJ, Popowitz L, et al: An experimental hepatorenal syndrome. Surg Gynecol Obstet 131:34-40, 1970.
13. Arroyo V, Bosch J, Gaya J, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 94:198-201, 1981.
14. Genoud E, Gonvers JJ, Schaller MD, et al: Valeur pronostique du système rénine-angiotensine dans la réponse à la restriction sodée et le pronostic de l'ascite cirrhotique d'origine alcoolique. Schweiz Med Wochenschr 116:463-9, 1986.
15. Llach J, Ginès P, Arroyo V, et al: Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 94:482-7, 1988.
16. Epstein M: Renal sodium handling in liver disease In: Epstein M (ed): The kidney in liver disease (ed 4). Philadelphia, Hanley and Belfus, 1996.
17. Schedl HP, Bartter FC: An explanation for experimental correction of the abnormal water diuresis in cirrhosis. J Clin Invest 39:248-61, 1960.
18. Chaimovitz C, Szylman P, Alroy G, Better OS: Mechanism of increased renal tubular sodium reabsorption in cirrhosis. Am J Med 52:198-202, 1972.
19. Levy M: Sodium retention in dogs with cirrhosis and ascites: efferent mechanisms. Am J Physiol 233:F586-92, 1977.
20. López-Novoa JM, Rengel MA. Rodicio JL, Hernando L: A micropuncture study of salt and water retention in chronic experimental cirrhosis. Am J Physiol 232:F315-18, 1977.
21. Rochman J, Chaimovitz C, Szylman P, Better OS: Tubular handling of sodium and phosphate in cirrhosis with salt retention. Nephron 20:95-100, 1978.
22. Wilkinson SP, Jowett TP, Slater JDH, et al: Renal sodium retention in cirrhosis: relation to aldosterone and nephron site. Clin Sci 56:169-77, 1979.
23. Angeli P, Gatta A, Caregaro L, et al: Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. Eur J Clin Invest 20:111-7, 1990.
24. Papper S, Rosenbaum JD: Abnormalities in the excretion of water and sodium in "compensated" cirrhosis of the liver. J Lab Clin Med 40:523-30, 1952.
25. Bosch J, Arroyo V, Rodés J. Hepatic and systemic hemdoynamics and the renin-angiotensin-aldosterone system in cirrhosis. In: Epstein M (ed): The kidney in liver disease (ed 2). New York, Elsevier Biomedical, 1983.
26. Lieberman FL, Reynolds TB: Plasma volume in cirrhosis of the liver: its relation to portal hypertension, ascites, and renal failure. J Clin Invest 46:1297-1307, 1967.
27. Bernardi M, Trevisani F, Santini C, et al: Aldosterone related blood volume expansion in cirrhosis before and after the early phase of ascites formation. Gut 24:761-6, 1983.
28. Caregaro L, Lauro S, Angeli P, et al: Renal water and sodium handling in compensated liver cirrhosis: mechanism of the impaired natriuresis after saline loading. Eur J Clin Invest 15: 360-5, 1985.
29. Wood LJ, Massie D, McLean AJ, Dudley FJ: Renal sodium retention in cirrhosis: tubular site and relation to hepatic dysfunction. Hepatology 8:831-6, 1988.
30. La Villa G, Salmerón JM, Arroyo V, et al: Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology 102:2114-9, 1992.
31. Bernardi M, Di Marco C, Trevisani F, et al: Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology 105:188-93, 1993.
32. Trevisani F, Bernardi M, Gasbarrini A, et al: Bed-rest-induced hypernatriuresis in cirrhotic patients without ascites: does it contribute to maintain "compensation"? J Hepatol 16:190-6, 1992.
33. Simon MA, Diez J, Prieto J: Abnormal sympathetic and renal response to sodium restriction in compensated cirrhosis. Gastroenterology 101:1354-60, 1991
34. Shear L, Hall PW, Gabuzda GJ: Renal failure in patients with cirrhosis of the liver. II. Factors influencing maximal urinary flow rate Am J Med 39:199-209, 1966.
35. Arroyo V, Clària J, Saló J, Jiménez W: Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 14:44-58, 1994.
36. Vaamonde CA: Renal water handling in liver disease. In: Epstein M (ed): The kidney in liver disease (ed 4) Philadelphia, Hanlcy and Belfus, 1996.
37. McCullough AJ, Mullen KD, Kalhan SC: Measurements of total body and extracellular water in cirrhotic patients with and without ascites. Hepatology 14:1103-11, 1991
38. Papper S, Saxon L: The diuretic response to administered water in patients with liver disease. II. Laennec's cirrhosis of the liver. Arch Intern Med 103:750-7, 1959.
39. Arroyo V, Rodés J, Gutiérrez-Lizarraga MA, Revert L: Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 21:249-56, 1976.
40. Ginès P, Sánchez Fueyo A, Fernández-Esparrach G, et al: Prognostic value of water excretion in cirrhosis with ascites. J Am Soc Nephrol, 1996 (in press) (abstract).
41. Boyer TD, Zia P, Reynolds TB: Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 77:215-22, 1979.
42. Pérez-Ayuso RM, Arroyo V, Camps J, et al: Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 26:72-80, 1984
43. Ginès P, Titó LI, Arroyo V, et al: Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94:1493-1502, 1988.
44. Ginès P, Abraham W, Schrier RW: Vasopressin in pathophysiological states. Semin Nephrol 14:384-97, 1994
45. Papper S, Belsky JL, Bleifer KH: Renal failure in Laennec's cirrhosis of the liver: I. Description of clinical and laboratory features. Ann Intern Med 51:759-73, 1959.
46. Vesin P: Late functional renal failure in cirrhosis with ascites: Pathophysiology, diagnosis and treatment. In: Martinin GA, Sherlock S (eds): Aktuelle Probleme der Hepatologie. Stuttgart, Georg Thieme Verlag, 1962.
47. Baldus WP, Feichter RN, Summerskill WHJ: The kidney in cirrhosis. I Clinical and biochemical features of azotemia in hepatic failure. Ann Intern Med 60:353-65, 1964.
48. Shear L, Kleinerman J, Gabuzda GJ: Renal failure in patients with cirrhosis of the liver: I. Clinical and pathologic characteristics. Am J Med 39:184-98, 1965.
49. Epstein M, Berk DP, Hollenberg NK, et al: Renal failure in the patient with cirrhosis. The role of active vasoconstriction Am J Med 49:175-85, 1970.
50. Kew MC, Brunt PW, Varma RR, et al: Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 2:504-10, 1971.
51. Sacerdoti D, Merlo A, Merkel C, et al: Redistribution of renal blood flow in patients with liver cirrhosis. The role of renal PGE2. J Hepatol 2:253-61, 1986.
52. Schroeder ET, Shear L, Sancetta SM, Gabuzda GJ: Renal failure in patients with cirrhosis of the liver. III. Evaluation of intrarenal blood flow by para-amino-hippurate extraction and response to angiotensin. Am J Med 43:887-96, 1967.
53. Lancestremere RG, Davidson PL, Earley LE, et al: Renal failure in Laennec's cirrhosis. II. Simultaneous determination of cardiac output and renal hemodynamics. J Clin Invest 41: 1922-7, 1962.
54. Platt JF, Marn CS, Baliga PK, et al: Renal dysfunction in hepatic disease: early identification with renal Duplex Doppler US in patients who undergo liver transplantation. Radiology 183:801-6, 1992.
55. Colli A, Coccioli M, Riva C, et al: Abnormal renovascular impedance in patients with hepatic cirrhosis detection with duplex US. Radiology 187:561-9, 1993.
56. Sacerdoti D, Bolognesi M, Merkel C, et al: Renal vasoconstriction in cirrhosis evaluated by Duplex Doppler ultrasonography. Hepatology 17-219-24, 1993.
57. Maroto A, Ginès A. Saló J, et al: Diagnosis of functional renal failure of cirrhosis by Doppler sonography. Prognostic value of resistive index. Hepatology 20:839-44, 1994.
58. Papadakis MA, Arieff AI: Unpredictability of clinical evaluation of renal function in cirrhosis: a prospective study. Am J Med 82:945-52, 1987.
59. Caregaro L, Menon F, Angeli P, et al: Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis Arch Intern Med 154:201-5, 1994.
60. Levey AS, Madaio MP, Perrone RD: Laboratory assessment of renal disease: clearance, urinalysis, and renal biopsy. In: Brenner BM, Rector FC (eds): The kidney (ed 4). W. B Saunders, 1991.
61. Arroyo V, Ginès P, Gerbes A, et al: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23:164-76, 1996.
62. Bosch J. Garcia-Pagán JC, Feu F, Pizcueta MP: Portal Hypertension. In: Prieto J, Rodés J, Shafritz DA (eds): Hepatobiliary diseases. Berlin, Springer-Verlag, 1992.
63. Grossman HJ, Grossman VL, Bhathal PS: Intrahepatic vascular resistance in cirrhosis. In: Bosch J, Groszmann RJ (eds): Portal hypertension: Pathophysiology and treatment. Oxford, Blackwell Scientific Publications, 1994
64. Scaffner F, Popper H: Capillarization of hepatic sinusoids in man. Gastroenterology 44:239-42, 1963.
65. Orrego H, Medline A, Blendis LM, et al: Collagenisation of the Disse space in alcoholic liver disease. Gut 20:673-9, 1979.
66. Bhathal PS, Grossman HJ: Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1:325-37, 1985.
67. Grossman HJ, Grossman VL, Bhathal PS: Enhanced vasoconstrictor response of the isolated perfused cirrhotic rat liver to humoral vasoconstrictor substances found in portal venous blood. J Gastroenterol Hepatol 7:283-7, 1992.
68. Pinzani M: Stellate hepatic (Ito) cells.Expanding roles for a liver-specific pericyte. J Hepatol 22:234-9, 1995.
69. Friedman SL: The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 328:1828-35, 1993.
70. Ramadori G: The stellate cell (Ito-cell, fat-storing cell, lipocyte, perisinusoidal cell) of the liver. New insights into pathophysiology of an intringuing cell Virchows Archiv B Cell Pathol 61:147-58, 1991.
71. Ballardini G, Fallini G, Biagini F, et al: Desmin and actin in the identification of Ito cells and in monitoring their evolution to myofibroblasts in experimental liver fibrosis. Virchows Archiv B Cell Pathol 56:45-9, 1988.
72. Pinzani M, Failli P, Ruocco C, et al: Fat-storing cells as liver-specific pericytes Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest 90:642-6, 1992.
73. Kawada N, Tran-Thi TA, Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin-1 and nitric oxide in the regulation of the sinusoidal tonum. Eur J Biochem 213:815-23, 1993.
74. Bauer M, Paquette NC, Zhang JX, et al: Chronic ethanol consumption increases hepatic sinusoidal contractile response to endothelin-1 in the rat. Hepatology 22:1565-76, 1995.
75. Zhang JX, Pegoli W, Clemens MG: Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physiol 29:G624-32, 1994.
76. Pinzani M, Milani S, De Franco R, et al: Endothelin 1 is over-expressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 110:434-548, 1996.
77. Bataller R, Ginès P, Nicolás JM, et al: Vasopressin induces contraction and stimulates mitogen-activated protein kinases in cultured human hepatic stellate cells. J Hepatol 25(suppl 1):106, 1996 (abstract).
78. Rockey DC, Weisiger RA: Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 24:233-40, 1996.
79. Benoit JN, Granger DN: Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 6 287-98, 1986.
80. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 87:1120-6, 1984
81. Vorobioff J, Bredfeldt JE, Groszmann RJ: Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 244:G52-7, 1983.
82. Bosch J, Enriquez R, Groszmann RJ, Storer EH: Chronic bile duct ligation in the dog: hemodynamic characterization of a portal hypertension model. Hepatology 3:1002-7, 1983.
83. Kotelanski B, Groszmann R, Cohn JN: Circulation times in the splanchnic and hepatic beds in alcoholic liver disease. Gastroenterology 63 102-11, 1972.
84. Sato S, Ohnishi K, Sugita S, et al: Splenic artery and superior mesenteric artery blood flow: nonsurgical Doppler US measurement in healthy subjects and patients with chronic liver disease. Radiology 164:347-52, 1987.
85. Korthuis RJ, Kinden DA, Brimer GE, et al: Intestinal capillary filtration in acute and chronic portal hypertension. Am J Physiol 254:G339-45, 1988.
86. Benoit JN, Granger DN: Intestinal microvascular adaptation to chronic portal hypertension in the rat. Gastroenterology 94: 471-6, 1988.
87. Rector WG: Portal hypertension: a permissive factor only in the development of ascites and variceal bleeding. Liver 6:221-6, 1986.
88. Morali GA, Sniderman KW, Deitel KM, et al: Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 16:249-50, 1992.
89. Bosch J, Arroyo V, Betriu A, et al: Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 78:92-9, 1980.
90. Castells A, Saló J, Planas R, et al: Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology 20:584-91, 1994.
91. Orloff MJ: Pathogenesis and surgical treatment of intractable ascites associated with alcoholic cirrhosis. Ann N Y Acad Sci 170:213-38, 1970.
92. Franco D, Vons C, Traynor, de Smadja C: Should portosystemic shunt be reconsidered in the treatment of intractable ascites in cirrhosis? Arch Surg 123:987-91, 1988.
93. Quiroga J, Sangro B, Nuñez M, et al: Transjugular intrahepatic portosystemic shunt in the treatment of refractory ascites. Effect on clinical, renal, humoral and hemodynamic parameters. Hepatology 21:986-94, 1995
94. Ochs A, Rössle M, Haag K, et al: The transjugular intrahepatic portosystemic stent shunt procedure for refractory ascites. N Engl J Med 332:1192-7, 1995.
95. Murray JF, Dawson AM, Sherlock S: Circulatory changes in chronic liver disease. Am J Med 32:358-67, 1958.
96. Kontos HA, Shapiro A, Mauck HP, Patterson L: General and regional circulatory alterations in cirrhosis of the liver. Am J Med 57:526-35, 1964.
97. Abelmann WH: Hyperdynamic circulation in cirrhosis: a historical perspective. Hepatology 20:1356-8, 1994.
98. Groszmann RJ: Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 20:1359-63, 1994.
99. Fernández-Seara J, Prieto J, Quiroga J, et al: Systemic and regional hemodynamics in patients with liver cirrhosis and asciles with and without functional renal failure. Gastroenterology 97:1304-12, 1989
100. Maroto A, Ginès P, Arroyo V, et al: Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction Hepatology 17:788-93, 1993.
101. Meng H, Lin H, Tsai Y, et al: Relationship between the severity of cirrhosis and haemodynamic values in patients with cirrhosis J Gastroenterol Hepatol 9:148-53, 1994
102. Rodríguez-Pérez F, Isales CM, Groszmann RJ: Platelet cytosolic calcium, peripheral hemodynamics, and vasodilatory peptides in liver cirrhosis. Gastroenterology 105:863-7, 1993.
103. Schrier RW, Caramelo C: Hemodynamics and hormonal alterations in hepatic cirrhosis. In: Epstein M (ed): The kidney in liver disease (ed 3) Baltimore, Williams and Wilkins, 1988.
104. Norris SH, Buell JC, Kurtzman NA: The pathophysiology of cirrhotic edema: a reexamination of the "Underfilling" and "Overflow" hypotheses. Semin Nephrol 7:77-82, 1987.
105. Fernández-Rodríguez F, Prieto J, Zozaya M, et al: Arteriovenous shunting, hemodynamic changes, and renal sodium retention in liver cirrhosis. Gastroenterology 104:1139-45, 1993.
106. Vallance P, Moncada S: Hyperdynamic circulation in cirrhosis: A role for nitric oxide? Lancet 337:776-8, 1991.
107. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology Pharmacol Rev 43:109-42, 1991.
108. Lowenstein CJ, Dinerman JL, Snyder SH: Nitric oxide: a physiologic messenger. Ann Intern Med 120:227-37, 1994.
109. Ros J, Jiméncz W, Lamas S, et al: Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology 21:554-60, 1995.
110. Niederberger M, Ginès P, Tsai P, et al: Increased aortic cyclic guanosine monophosphate concentration in experimental cirrhosis in rats: evidence for a role of nitric oxide in the pathogenesis of arterial vasodilation in cirrhosis. Hepatology 21: 1625-31, 1995.
111. Martin PY, Xu DL, Niederberger M, et al: Upregulation of the endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol 39:F494-9, 1996.
112. Morales M, Jiménez W, Pérez-Sala D, et al: Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites Hepatology. 1997 (in press).
113. Clària J, Jiménez W, Ros J, et al: Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology 15:343-9, 1992.
114. Niederberger M, Martin PY, Ginès P, et al: Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in rats with cirrhosis and ascites. Gastroenterology 109:1624-30, 1995.
115. Battista S, Bar F, Mengozzi G, et al: Systemic and portal nitric oxide and endothelin-1 levels in cirrhotic patients. J Hepatol 23(suppl 1):73, 1995 (abstract).
116. Guarner C, Soriano G, Tomas A, et al: Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship with endotoxemia. Hepatology 18:1139-43, 1993.
117. Sogni P, Garnier P, Gadano A, et al: Endogenous pulmonary nitric oxide production measured from exhaled air is increased in patients with severe cirrhosis. J Hepatol 23-471-3, 1995
118. Matsumoto A, Ogura K, Hirata Y, et al Increased nitric oxide in the exhaled air of patients with decompensated liver cirrhosis. Ann Intern Med 123:110-3, 1995.
119. Albillos A, Rossi I, Cacho G, et al: Enhanced endothelium-dependent vasodilation in patients with cirrhosis. Am J Physiol 268:G459-G464, 1995.
120. Campillo B, Chabrier PE, Pelle G, et al: Inhibition of nitric oxide synthesis in the forearm arterial bed of patients with advanced cirrhosis. Hepatology 22:1423-9, 1995.
121. !21. Arroyo V, Ginès P, Jiménez W, Rodés J: Ascites, renal failure, and electrolyte disorders in cirrhosis. Pathogenesis, diagnosis, and treatment. In: McIntyre N, Benhamou JP, Bircher J, Rizetto M, Rodés J (eds): Textbook of clinical hepatology (ed 1). Oxford, Oxford Medical Press, 1991.
122. Bernardi M, Trevisani F, Gasbarrini G: The renin-angiotensin-aldosterone system in liver disease. In: Bomzon A, Blendis LM (eds): Cardiovascular complications of liver disease. Boca Raton, CRC Press, 1990
123. Epstein M: Renin-angiotensin system in liver disease. In: Epstein M (ed): The kidney in liver disease (ed 4). Philadelphia, Hanley and Belfus, 1996.
124. Henriksen JH, Ring-Larsen H, Christensen NJ: Autonomic nervous function in liver disease. In: Bomzon A, Blendis LM (eds): Cardiovascular complications of liver disease. Boca Raton, CRC Press, 1990.
125. Wilkinson SP, Smith IK, Williams R: Changes in plasma renin activity in cirrhosis: a reappraisal based on studies in 67 patients and "low-renin" cirrhosis. Hypertension 1:125-9, 1979.
126. Saló J, Ginès A, Anibarro L, et al: Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. Hepatology 22:479-87, 1995.
127. Arroyo V, Ginès P, Jiménez W: Renal circulation and pathogenesis of functional renal failure in cirrhosis. In: Boinzon A, Blendis LM (eds): Cardiovascular complications of liver disease. Boca Raton, CRC Press, 1990.
128. Schroeder ET, Anderson GH, Goldman SH, Streeten DHP: Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis. Kidney Int 9:511-9, 1976.
129. Arroyo V, Bosch J, Mauri M, et al: Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 11:221-9, 1981.
130. Pariente EA, Bataille C, Bercoff E, et al: Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 88:1255-9. 1985.
131. Clària J, Jiménez W, Arroyo V, et al: Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 100:494-501, 1991.
132. Asbert M, Ginès A, Ginès P, et al: Circulating levels of endothelin in cirrhosis. Gastroenterology 104:1485-91, 1993.
133. Moller S, Emmeluth C, Henriksen JH: Elevated circulating plasma endothelin-1 concentrations in cirrhosis. J Hepatol 19:285-90, 1993.
134. Moller S, Gülberg V, Henriksen JH, Gerbes AL: Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic hemodynamics. J Hepatol 23:135-44, 1995.
135. Leivas A, Jiménez W, Lamas S, et al: Endothelin-1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites. Gastroenterology 108:1842-8, 1995.
136. Moore K, Wendon J, Frazer M, et al: Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 327:1774-8, 1992.
137. Ginès P, Jiménez W, Arroyo V, et al: Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology 8:636-42, 1988.
138. Warner L, Skorecki K, Blendis LM, Epstein M: Atrial natriuretic factor and liver disease. Hepatology 17:500-13, 1993.
139. La Villa G, Romanelh RG, Raggi VC, et al: Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 16:156 61, 1992.
140. Cottier C, Matter L, Weidman P, et al: Renal reponse to low-dose infusion of atrial natriuretic peptide in normal man. Kidney Int 34(suppl 25):S72-8, 1988.
141. Warner LC: The role of resistance to atrial natriuretic peptide and the pathogenesis of sodium retention in hepatic cirrhosis. In: Brenner BM, Laragh J (eds). Progress in atrial peptide research. New York, Raven Press, 1989.
142. Angeli P, Jiménez W, Arroyo V, et al: Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 20:948-54, 1994.
143. Yang SS, Korula J, Sundheimer JE, et al: Digoxin-like immunoreactivity substances in chronic liver disease. Hepatology 9:363-9, 1989
144. LaVilla G, Asbert M, Jiménez W, et al: Natriuretic hormone activity in the urine of cirrhotic patients. Hepatology 12:467-75, 1990.
145. Saló J, Jiménez W, Kuhn M, et al: Urinary excretion of urodilatin in patients with cirrhosis Hepatology, 1996 (in press).
146. Atucha NM, Cegarra M, Ramírez A, et al: Pressure diuresis and natriuresis in cirrhotic rats. Am J Physiol 265:G1045-9, 1993.
147. Laffi G, La Villa G, Pinzani M, Gentilini P: Lipid-derived autacoids and renal function in liver cirrhosis. In: Epstein M (ed): The kidney in liver disease (ed 4). Philadelphia, Hanley and Belfus, 1996.
148. Arroyo V, Planas R, Gaya J, et al: Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 13:271-8, 1983.
149. Quintero E, Ginès P, Arroyo V, et al: Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites. Nephron 42 298-303, 1986.
150. Llach J, Ginès P, Arroyo V, et al: Effect of dipyridamole on kidney function in cirrhosis. Hepatology 17:59-64, 1993.
151. Raij L: Nitric oxide and the kidney. Circulation 87 (suppl V):26-9, 1993.
152. Garcia-Estañ J, Atucha N, Mario J, et al: Increased endothelium-dependent renal vasodilation in cirrhotic rats. Am J Physiol 267:R549-53,1994.
153. Ros J, Clària J, Jiménez W et al: Role of nitric acid and prostaglandin in the control of renal perfusion in experimental cirrhosis. Hepatology 22:915-20, 1995.
154. Greco AV, Porcelli G, Ghirlanda G, et al: L'escrezione di callicreina urinaria nella cirrosis epatica. Min Med 66:1504-8, 1975.
155. Pérez-Ayuso RM, Arroyo V, Camps J, et al: Renal kallikrein excretion in cirrhotics with ascites. relationship to renal hemodynamics. Hepatology 4:247-52, 1984.
156. Zipser RD, Kerlin P, Hoefs JC, et al: Renal kallikrein excretion in alcoholic cirrhosis. Relationship to other vasoactive systems. Am J Gastroenterol 75:183-7, 1981.
157. Hattori K, Hasumura Y, Takeuchi J: Role of renal kallikrein in the derangement of sodium and water excretion in cirrhotic patients. Scand J Gastroenterol 19:844-8, 1984.
158. Palmer BF, Alpern RJ, Seidin DW: Pathopysiology of edema formation. In: Seldin DW, Giebisch G (eds): The kidney: physiology and pathophysiology (ed 2). New York, Raven Press, 1992.
159. Ginès P, Humphreys MH, Schrier RW: Edema. In: Massry SG, Glassock RJ (eds): Textbook of Nephrology (ed 3). Baltimore, Williams and Wilkins, 1995.
160. Schrier RW: Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med 113:155-9, 1990.
161. Witte MH, Witte CL, Dumont AE: Progress in liver disease: physiological factors involved in the causation of cirrhotic ascites. Gastroenterology 61:742-0, 1971.
162. Witte CL, Witte MH, Dumont AE: Lymph imbalance in the genesis and perpetuation of the ascites syndrome in hepatic cirrhosis. Gastroenterology 78:1059-68, 1980.
163. Lieberman FL, Ito S, Reynolds TB: Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a spontaneous reduction in glomerular filtration rate (GFR), and a fall in GFR during drug-induced diuresis. J Clin Invest 48:975-81, 1969.
164. Lieberman FL, Denison EK, Reynolds TB: The relationship of plasma volume, portal hypertension, ascites. and renal sodium retention in cirrhosis: the overflow theory of ascites formation. Ann N Y Acad Sci 170:202-12, 1970.
165. Wensing G, Sabra R, Branch RA. The onset of sodium retention in experimental cirrhosis in rats is related to a critical threshold of liver function. Hepatology 11:779-86, 1990.
166. Wensing G, Sabra R, Branch RA: Renal and systemic hemodynamics in experimental cirrhosis in rats: relation to hepatic function. Hepatology 12:13-9, 1990.
167. Rector WG Jr, Lewis F, Robertson AD, Everson GT: Renal sodium retention complicating alcoholic liver disease: relation to portosystemic shunting and liver function. Hepatology 12:455-459, 1990.
168. Kostreva DR, Castaner A, Kampine JP: Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nervous activity. Am J Physiol 238:R390-4, 1980.
169. Levy M, Wexler MJ: Hepatic denervation alters first-phase urinary sodium excretion in dogs with cirrhosis. Am J Physiol 253:F664-71, 1987.
170. Levy M, Wexler MJ: Sodium excretion in dogs with low grade caval constriction: role of hepatic nerves. Am J Physiol 253:F672-8, 1987
171. Unikowsky B, Wexler MJ, Levy M: Dogs with experimental cirrhosis of the liver but without intrahepatic hypertension do not retain sodium or form ascites. J Clin Invest 72:1594-1604, 1983.
172. Schrier RW, Arroyo V, Bernardi M, et al: Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8:1151-7, 1988
173. Schrier RW, Neiderbeger M, Weigert A, Ginès P. Peripheral arterial vasodilation: determinant of functional spectrum of cirrhosis. Semin Liver Dis 14:14-22, 1994.
174. Henriksen JH, Bendtsen F, Gerbes AL, et al: Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta adrenergic blockade and atrial natriuretic factor. Hepatology 16 1163-70, 1992.
175. Henriksen J, Moller S: Hemodynamics, distribution of blood volume, and kinetics of vasoactive substances in cirrhosis. In: Epstein M (ed): The kidney in liver disease (ed 4). Philadelphia, Hanley & Belfus, 1996.
176. Wong PY, Carroll RE, Lipinski TL, Capone RR. Studies on the renin-angiotensin-aldosterone system in patients with cirrhosis and ascites: effect of saline and albumin infusion. Gastroenterology 77:1171-6, 1979.
177. Shapiro MD, Nichols KM, Groves BM, et al: Interrelationship between cardiac output and vascular resistance as determinants of "effective arterial blood volume" in patients with cirrhosis. Kidney Int 28: 206-11, 1985.
178. Nicholls KM, Shapiro MD, Van Putten VJ, et al: Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates, normal clearance rates, and suppressibility by central blood volume expansion. Circ Res 56:457-61, 1985.
179. Blendis LM, Sole MJ, Campbell P, et al: The effect of peritoneovenous shunting on catecholamine metabolism in patients with hepatic ascites. Hepatology 7:143-8, 1987.
180. Epstein M: Renal effects of head-out water immersion in humans: a 15-year update. Physiol Rev 72:563-621, 1992.
181. Guevara M, Ginès P, Fernández-Esparrach G, et al: Effects of normalization of vasoconstrictor systems on renal function in cirrhotic patients with hepatorenal syndrome. J Hepatol 25(suppl 1):71, 1996 (abstract).
182. Salmerón JM, Ruiz del Arbol L, Ginès A, et al: Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology 17:800-6, 1993
183. Albillos A, LLedó JL, Rossi I, et al: Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and liver and renal function. Gastroenterology 109:1257-65, 1995.